MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.omton.2026.201201

Медицинская библиотека · Molecular therapy. Oncology · 2026

Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager.

Choi Moon Jung, So Eui Young, Akosman Bedia, Lee Young Eun, Raufi Alexander G, Reginato Anthony M, Chen Clark C, Lawler Sean E, Wong Eric T, Liang Olin D

СтатьяПеревод пока не подготовлен

Аннотация

Recent clinical trials show that CAR T cell therapies can initially blunt tumor growth in patients with glioblastoma (GBM). However, therapeutic efficacy remains limited by the immunosuppressive tumor microenvironment and restricted immune cell trafficking across the blood-brain barrier (BBB). To counteract these challenges, we have utilized the oncolytic adenovirus (OV) Ad5-Δ24-RGD as a platform to overexpress a bispecific T cell engager (BiTE) targeting both CD3 on T cells and the GBM-specific tumor associated antigen IL-13Rα2. We first demonstrated that OV-BiTE can significantly increase the recruitment of T cells to GBM, both in vitro and in vivo. Moreover, OV-BiTE treatment also markedly enhanced CAR T cell infiltration and tumor cytotoxicity in a GBM-BBB spheroid model, possibly through downregulation of endothelial junction protein expression. We then showed that intratumoral injection of OV-BiTE followed by infusion of combined EGFR and EGFRvIII CAR T cells was more effective than OV-BiTE supplemented with either CAR T therapy alone and led to significant tumor reduction in a GBM xenograft mouse model. In conclusion, our multimodal OV-BiTE plus CAR T cell immunotherapy is capable of overcoming the immunosuppressive tumor microenvironment and GBM resistance to treatment.

Для цитирования: Choi Moon Jung, So Eui Young, Akosman Bedia, Lee Young Eun, Raufi Alexander G, Reginato Anthony M, Chen Clark C, Lawler Sean E, Wong Eric T, Liang Olin D. Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager.. Molecular therapy. Oncology. 2026. DOI: 10.1016/j.omton.2026.201201.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.